Cargando…
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
BACKGROUND: Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed to identify biomarker(s) indicative of IL-13 activation lik...
Autores principales: | Gottlow, Mattis, Svensson, David J., Lipkovich, Ilya, Huhn, Monika, Bowen, Karin, Wessman, Peter, Colice, Gene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637533/ https://www.ncbi.nlm.nih.gov/pubmed/31315668 http://dx.doi.org/10.1186/s12890-019-0889-4 |
Ejemplares similares
-
Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma
por: Carlsson, Mats, et al.
Publicado: (2019) -
Using online technologies to improve diversity and inclusion in cognitive interviews with young people
por: Upadhyay, Ushma D., et al.
Publicado: (2020) -
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020) -
Surgical treatment of bronchial asthma by resection of the laryngeal nerve
por: Kurbon, Ubaidullo, et al.
Publicado: (2015) -
Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)